Amdoxovir

Amdoxovir
Clinical data

ATC code	none
Identifiers
IUPAC name [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
CAS Number	145514-04-1^Y
PubChem (CID)	124088
ChemSpider	110576^Y
UNII	54I81H0M9C^Y
KEGG	D02890^Y
ChEMBL	CHEMBL458876^Y
NIAID ChemDB	005431
Chemical and physical data
Formula	C₉H₁₂N₆O₃
Molar mass	252.23 g/mol
3D model (Jmol)	Interactive image
SMILES n2c1c(nc(nc1n(c2)[C@@H]3O[C@@H](OC3)CO)N)N
InChI InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1^Y Key:RLAHNGKRJJEIJL-RFZPGFLSSA-N^Y
(verify)

Amdoxovir is a nucleoside reverse transcriptase inhibitor (NRTI) undergoing research for the treatment of HIV/AIDS. It was discovered by Raymond F. Schinazi (Emory University) and C.K. Chu (University of Georgia). It is being developed by RFS Pharma.^[1] Currently, it is in Phase II clinical studies.

References

↑ "Amdoxovir". AIDSmeds.com. January 13, 2009. Archived from the original on March 21, 2008. Retrieved March 21, 2008.

Murphy RL, Kivel NM, Zala C, Ochoa C, Tharnish P, Mathew J, Pascual ML, Schinazi RF (2010). "Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals". Antivir Ther. 15 (2): 185–192. doi:10.3851/IMP1514. PMID 20386073.

Entry/fusion inhibitors
(Discovery and development)

Nucleoside and nucleotide (NRTI)	Nucleoside analogues/NRTIs: Abacavir (ABC)°^# Didanosine (ddI) Emtricitabine (FTC)° Lamivudine (3TC)°^# Stavudine (d4T)^# Zidovudine (AZT, ZDV)^# Amdoxovir^† Apricitabine^† Censavudine^† Elvucitabine^† Racivir^† Stampidine^† Zalcitabine (ddC)^◊ Nucleotide analogues/NtRTIs: Tenofovir disoproxil (TDF)°^# Tenofovir alafenamide (TAF)

Non-nucleoside (NNRTI) (Discovery and development)	(1st generation) Efavirenz (EFV)°^# Nevirapine (NVP)^# Delavirdine (DLV)^◊ (2nd generation) diarylpyrimidines (Etravirine (ETR) Rilpivirine (RPV)°) Doravirine

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))

Protease Inhibitors (PI)
(Discovery and development)

1st generation	Amprenavir (APV)^◊ Fosamprenavir (FPV) Indinavir (IDV)^◊ Lopinavir (LPV) Nelfinavir (NFV) Ritonavir (RTV)^# Saquinavir (SQV)^#

2nd generation	Atazanavir (ATV)°^# Darunavir (DRV)°^# Tipranavir (TPV)

Pharmacokinetic boosters

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)

Transcription inhibitors	Tat antagonists

Translation inhibitors	Trichosanthin

Other	Abzyme BIT225^† Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) KP-1461^† Foscarnet Fosdevirine^† Griffithsin Hydroxycarbamide Miltefosine Portmanteau inhibitors Scytovirin Seliciclib^† Synergistic enhancers Tre recombinase Zinc finger protein transcription factor

Failed agents	Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine Lodenosine Loviride Mozenavir Palinavir Telinavir

°DHHS recommended initial regimen options. ^◊Formerly or rarely used agent.

This article is issued from Wikipedia - version of the 9/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.